Popular Vaccine Stabilizer Triggers Unwanted Immune Response
Adding sugar shields to the viral foldon domain reduces binding for some antibodies, but fails to stop unwanted immune activation in naive subjects.
Protein subunit and mRNA vaccines rely on specialized structural domains to hold fragile viral proteins in the correct shape, but a new study reveals that one of the most popular stabilizing tools triggers unexpected immune blind spots. Researchers investigated the Foldon trimerization domain, a tiny protein segment derived from the T4 bacteriophage that holds together viral antigens in FDA-approved vaccines such as AREXVY and ABRYSVO for respiratory syncytial virus.
While the Foldon domain successfully stabilizes vital vaccine antigens, previous clinical trials showed it also provokes unwanted off-target antibody responses in humans and animals. To solve this problem, a team led by scientists at the University of California Santa Cruz and the University of Georgia set out to build an invisible molecular shield around the domain by adding sugar molecules through genetic engineering. The findings were published in PLOS One, detailing both the potential and the strict structural limits of modifying viral subunit components.
How Scientists Tried to Hide the Foldon Domain Using Engineered Sugars
The research team focused on modifying a computationally optimized broadly reactive antigen, known as a COBRA influenza hemagglutinin protein, by appending the Foldon domain to its tail end. Using structural models of the T4 fibritin protein, the authors selected three solvent-exposed sites, designated as Site 1, Site 2, and Site 3, to introduce specific amino acid sequences that signal cells to attach N-linked glycan carbohydrates. These sugary additions are naturally used by host cells to coat proteins and evade detection by the immune system.

When the researchers expressed these redesigned proteins in mammalian Chinese hamster ovary cells, single-site mutations successfully formed stable trimers that closely mirrored the unmodified wild-type protein. However, attempting to combine two of these glycosylation sites into a single protein caused the trimeric structure to fall apart into monomers. This outcome pointed to a rigid boundary in how much genetic tampering the Foldon domain can tolerate before its core stability collapses.
Testing the Shield Against Monoclonal Antibodies and Mouse Sera
The investigators then tested whether the added sugar coatings could successfully block antibody recognition using enzyme-linked immunosorbent assays and biolayer interferometry. When exposed to sera from mice previously immunized with respiratory syncytial virus antigens containing a wild-type Foldon, the single-site glycan mutants at Site 1 and Site 3 demonstrated a statistically significant reduction in binding reactivity.

However, when the team vaccinated a new group of naive mice with the glycan-shielded antigens, the animals still generated robust antibody responses directly targeting the Foldon domain. The sugar-modified vaccines failed to significantly lower overall Foldon immunogenicity in subjects with no prior exposure. Further biochemical analyses utilizing mass spectrometry and enzymatic deglycosylation revealed that the sugar occupancy at the target sites was less than 50 percent. Moreover, mutating the underlying amino acids alone accounted for much of the altered antibody binding, independent of the attached sugars.
What These Limits Mean for Future Vaccine Design
As biotechnology researchers continue to develop advanced subunit vaccines for viral pathogens, managing off-target immunity remains a critical priority. The study highlights that while introducing glycosylation motifs can alter local protein antigenicity, single-site shields are currently insufficient to prevent the immune system from recognizing the underlying Foldon scaffold. The authors conclude that alternative strategies, such as developing entirely self-trimerizing viral antigens without exogenous helper domains, will likely be necessary to prevent unintended immune reactions in future clinical applications.
The research was published in PloS one on January 1, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Dzimianski, John V.., et al. “Immunogenicity of the Foldon trimerization domain and efforts to shield it.” PLOS One, vol. 21, no. 11, November 13, 2026, pp. e0362571 Public Library of Science (PLoS), doi: 10.1371/journal.pone.0362571. <https://doi.org/10.1371/journal.pone.0362571>.
Cite this page:
- Posted by Rohan Kumar